Jay Alexander P M, Aldiwani Mohammed, O'Callaghan Michael E, Pearce Adam K, Huddart Robert A, Mayer Erik, Reid Alison H, Nicol David L
Department of Urology, Royal Marsden Hospital, London, UK.
Urology Unit, Flinders Medical Centre, Adelaide, Australia.
Eur Urol Open Sci. 2021 Jun 7;29:82-88. doi: 10.1016/j.euros.2021.04.008. eCollection 2021 Jul.
Late relapse (LR) of nonseminomatous germ cell tumour (NSGCT) is uncommon, with limited data published. LR is defined as relapse occurring after a disease-free interval of 2 yr.
To review features of NSGCT LR in a UK tertiary centre.
A total of 3064 patients were referred from January 2005 to December 2017. We identified patients who experienced LR after initial pathology demonstrated NSGCT and reviewed data for their original and LR presentation and management.
Outcomes included time to LR measured from the date of diagnosis, and overall survival. This was assessed using Cox proportional Hazards modelling, with stratification or adjustment for potential confounders.
We identified 101 patients with LR; the median time to LR was 96 mo. Forty-three patients (42.6%) experienced relapse after 10 yr. Univariable log-rank testing revealed that the median time to LR was significantly shorter for patients who had not received induction chemotherapy (iCTx; 54 mo, 95% confidence interval [CI] 48-108) than for those who did (112 mo, 95% CI 84-186; = 0.04). Patients who had received iCTx were less likely to have elevated tumour markers (36% vs 46%) and more likely to undergo initial surgical resection at LR compared to CTx-naïve patients. Postpubertal teratoma (PPT), yolk sac, and dedifferentiated elements predominated for patients with iCTx exposure, whereas active GCT or fibrosis predominated in postchemotherapy resections for CTx-naïve patients at LR. Forty-one men underwent postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) as part of their initial treatment for metastatic disease. Of these, 20 experienced LR in the retroperitoneum, with 18 undergoing repeat RPLND as part of their LR management. Fifteen of the repeat RPLND histopathology specimens had a PPT component. There have been 23 deaths overall; survival was worse for patients presenting with symptoms (13/36, 33%) and those receiving CTx and no surgery (10/17, 59%) at LR.
When LR of NSGCT occurs, it is frequently after an extended interval and is later among patients with prior iCTx, with PPT predominating. The high frequency of LR within the retroperitoneum following PC-RPLND reinforces the need for good-quality PC-RPLND.
We reviewed data for patients who had a late relapse of testicular cancer. We found that patients who did not receive chemotherapy as the first treatment for their initial diagnosis had a shorter time to relapse. Our results highlight the importance of long-term follow-up for testicular cancer.
非精原细胞瘤性生殖细胞肿瘤(NSGCT)的晚期复发(LR)并不常见,发表的数据有限。LR被定义为在无病间隔2年后发生的复发。
回顾英国一家三级中心NSGCT-LR的特征。
设计、设置和参与者:2005年1月至2017年12月共转诊3064例患者。我们确定了那些在初始病理显示为NSGCT后经历LR的患者,并回顾了他们初始和LR表现及治疗的数据。
结果包括从诊断日期开始测量的LR时间和总生存期。使用Cox比例风险模型进行评估,并对潜在混杂因素进行分层或调整。
我们确定了101例LR患者;LR的中位时间为96个月。43例患者(42.6%)在10年后复发。单变量对数秩检验显示,未接受诱导化疗(iCTx)的患者LR的中位时间(54个月,95%置信区间[CI]48-108)显著短于接受诱导化疗的患者(112个月,95%CI 84-186;P = 0.04)。与未接受过CTx的患者相比,接受iCTx的患者肿瘤标志物升高的可能性较小(36%对46%),在LR时更有可能接受初始手术切除。青春期后畸胎瘤(PPT)、卵黄囊和去分化成分在接受iCTx的患者中占主导,而在LR时未接受过CTx的患者化疗后切除标本中活性生殖细胞肿瘤或纤维化占主导。41名男性在初始治疗转移性疾病时接受了化疗后腹膜后淋巴结清扫术(PC-RPLND)。其中,20例在腹膜后复发,18例在LR治疗时接受了重复RPLND。15例重复RPLND组织病理学标本有PPT成分。总体共有23例死亡;LR时出现症状的患者(13/36,33%)和接受CTx且未手术的患者(10/17,59%)生存率较差。
当NSGCT发生LR时,通常是在较长间隔后,且在先前接受过iCTx的患者中较晚出现,以PPT为主。PC-RPLND后腹膜后LR的高发生率强化了高质量PC-RPLND的必要性。
我们回顾了睾丸癌晚期复发患者的数据。我们发现,初始诊断时未接受化疗作为首次治疗的患者复发时间较短。我们的结果强调了睾丸癌长期随访的重要性。